We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

4SC Announces Positive Top Line Data from Clinical Phase I TOPAS Study

News   May 30, 2014

 
4SC Announces Positive Top Line Data from Clinical Phase I TOPAS Study
 
 
Advertisement
 

RELATED ARTICLES

Adding Abemaciclib to Hormonal Therapy Reduces Risk of Cancer Recurrence in Patients With High-Risk Early HR+ HER2- Early Breast Cancer

News

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to trial results.

READ MORE

Olaparib Successfully Treats Prostate Cancers With Genetic Fault in Clinical Trial

News

Results from the PROfound trial have showed that olaparib – a drug called a PARP inhibitor – can be used successfully to treat prostate cancers with a "weakness" in their ability to repair damaged DNA.

READ MORE

Algorithms Uncover Cancers’ Unseen Genetic Losses and Gains

News

Scientists have created new mathematical tools that allow scientists to search the vast collection of DNA snippets and uncover whether there are either missing pieces or duplicates. These algorithms, dubbed HATCHet and CHISEL, could help to improve diagnosis and treatment.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE